Serum Institute of India (SII), the world’s largest vaccine manufacturer, has been tasked with no less than bringing an end to the global pandemic. The SII has pledged to deliver up to 2 billion vaccine doses in the coming years to COVAX, a global initiative to provide vaccine to lower- and middle-income countries—and it has already provided more doses to that initiative than any other vaccine maker. The SII is producing two vaccines. The first, Covishield, is one of only a few vaccines approved by the World Health Organization and is based on the COVID vaccine AstraZeneca developed. SII’s other vaccine, called Covavax, is being produced in partnership with American firm Novavax, and may provide a 1.1 billion–dose boon to global vaccine stocks starting later this year once it clears clinical trials. Poonawalla has hit some speed bumps in following through with his company’s global promises. A deadly surge in COVID-19 infections in India this spring forced Poonawalla to refocus distribution efforts at home. But in April, the CEO secured a $400 million investment from India’s government that he says will help the company produce an additional 30 million to 40 million Covishield doses per month and help India address its COVID-19 crisis. Poonawalla says that SII will resume exports once that happens, and countries around the world have reason to take him at his word: Before India’s current crisis Poonawalla demonstrated an unmatched commitment to global vaccine equity, providing low-cost vaccines to fight diseases like influenza, measles, and tetanus."> Adar Poonawalla |财欧宝竞技ob富 - 欧宝体育下载平台

世界上最伟大的50位领导人

排名
10
前一:9 下一个:11

阿达尔月Poonawalla

WGL 2021-Adar Poonwalla
Dhiraj Singh-Bloomberg /盖蒂图片社
  • 标题
    首席执行官
  • 联系
    印度血清研究所

普那瓦拉是印度血清研究所(SII)是世界上最大的疫苗制造商，其任务不亚于结束全球大流行。SII已承诺在未来几年向全球获取疫苗计划(一项向中低收入国家提供疫苗的全球倡议)提供多达20亿剂疫苗，而且它已经向该倡议提供了比任何其他疫苗制造商更多的疫苗剂量。欧宝球网站SII正在生产两种疫苗。第一种是Covishield，是世界卫生组织批准的为数不多的疫苗之一，以COVID疫苗为基础阿斯利康发展。SII公司的另一种名为Covavax的疫苗正在与美国Novavax公司合作生产，一旦临床试验通过，从今年晚些时候开始，可能会为全球疫苗库存提供11亿剂疫苗。普纳瓦拉在履行公司的全球承诺时遇到了一些障碍。今年春天，印度COVID-19感染人数激增，迫使普纳瓦拉将分发工作的重点重新放在国内。但今年4月，这位首席执行官从印度政府获得了4亿美元的投资，他说这笔投资将帮助公司每月额外生产3000万至4000万支covishishield，并帮助印度应对COVID-19危机。Poonawalla说，一旦发生这种情况，SII将恢复出口，世界各国有理由相信他的话:在印度目前的危机之前，Poonawalla表现出对全球疫苗公平的无与伦比的承诺，提供低成本疫苗来对抗流感、麻疹和破伤风等疾病。